Avantor Inc stock (US0543031027): shares trade lower after recent slide despite solid Q1 update

Avantor Inc shares on the New York Stock Exchange remain under pressure after a recent pullback, even as the US life sciences supplier reiterated its 2024 outlook following its latest quarterly report.

Avantor Inc shares on the New York Stock Exchange were softer in recent sessions, extending a pullback that followed the company’s latest quarterly update, even though the US-based life sciences supplier reaffirmed its full-year outlook according to a company filing and price data from NYSE as of 05/28/2026.

The stock traded at USD 24.30 on 05/28/2026 on the NYSE under the ticker AVTR, according to data published on the exchange’s website and recent market information from Morningstar as of 05/28/2026. In Germany, the stock was also quoted on Tradegate in euros on 05/28/2026, giving investors in the eurozone an additional access point to the name.

Avantor, headquartered in Radnor, Pennsylvania, had earlier reported its most recent quarterly results and reiterated its 2024 guidance, according to its investor relations materials and recent earnings documentation published on 05/03/2026. The company highlighted continued demand from its biopharma and advanced technologies customers, while also noting ongoing normalization in some laboratory spending categories compared with the peak-pandemic period.

The share price retreat over the past days comes after a stronger performance earlier in the year, leaving Avantor trading below recent highs but still above the low point of the last 12 months on the New York market. Trading volumes in New York on 05/28/2026 were broadly in line with recent averages, based on available quote data for AVTR on that date.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Avantor Inc
• Sector/industry: Life sciences tools, specialty materials and lab supplies
• Headquarters/country: Radnor, United States
• Core markets: Biopharma, healthcare, education, industrial and advanced technologies customers across North America, Europe and selected Asia-Pacific regions
• Key revenue drivers: Sales of laboratory consumables, production chemicals, single-use bioprocessing solutions and scientific services
• Home exchange/listing venue: New York Stock Exchange (AVTR)
• Trading currency: USD

Avantor Inc: core business model

Avantor Inc operates as a global provider of lab materials, consumables, equipment and related services that enable research, biopharmaceutical production and specialized manufacturing for customers in life sciences and advanced technologies.

Valuation metrics and multiples for Avantor Inc

On a valuation basis, Avantor Inc is currently assessed in the market using metrics such as the price-earnings ratio and enterprise-value-to-EBITDA multiple derived from its latest reported financials and the NYSE share price as of 05/28/2026. Based on the closing price around USD 24.30 and the most recently reported earnings per share for the last four quarters, data providers such as Morningstar indicate that the stock is trading on a mid-teens to low-20s P/E range as of late May 2026, placing it broadly in line with a number of listed life sciences tools peers.

Looking at enterprise-value-based measures, Avantor’s EV/EBITDA multiple calculated from its market capitalization, net debt from the latest balance sheet and trailing 12-month EBITDA suggests the company is being valued at a level comparable to other diversified lab supplies and consumables providers. Dividend yield remains modest, as Avantor has historically focused more on reinvestment and balance-sheet management than on cash distributions, which shapes how income-oriented investors may view the stock compared with higher-yielding names in the broader US market.

Conclusion

Avantor Inc shares on the New York Stock Exchange have eased back following the company’s latest quarterly update, even as management confirmed its 2024 guidance and pointed to steady underlying demand in core end markets. The current valuation, reflected in mid-teens to low-20s P/E and EV/EBITDA multiples as of late May 2026, positions the stock roughly in line with many US life sciences tools peers and provides a reference point for investors tracking how the market prices Avantor’s growth and margin prospects.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.